TranS1

About TranS1

TranS1 Inc. is a medical device company focused on developing and commercializing surgical approaches for the treatment of degenerative conditions affecting the lower lumbar spine. Originally incorporated as aXiaMed, Inc. in May 2000, the company rebranded to TranS1 Inc. in February 2003. The firm's history includes a significant transition when it acquired Baxano, Inc. in 2013, briefly operating as Baxano Surgical, Inc., before facing bankruptcy. The core TranS1 business and its primary technology were later salvaged by Quandary Medical, re-establishing the TranS1 brand.

The company's business model centers on the design, development, and sale of medical devices to surgeons and healthcare systems. Its commercial success is dependent on the adoption of its products by spine surgeons as a safe and effective alternative to traditional surgical treatments. TranS1 markets its products in the United States, Europe, and Latin America, serving spine surgeons who perform lumbar fusion procedures. Revenue is generated through the sale of its surgical systems and implants.

TranS1's flagship product is the AxiaLIF® (Axial Lumbar Interbody Fusion) system, a minimally invasive surgical platform. This system provides surgeons with a proprietary method to access the L5-S1 discs of the lumbar spine through a pre-sacral approach, which avoids cutting through critical back muscles and tissues. The key benefit of this technique is the reduction in patient trauma, leading to lower complication rates, shorter procedure times, reduced blood loss, and faster recovery periods compared to conventional spinal fusion surgery. The AxiaLIF+® system, a later generation, enables distraction and stabilization of the anterior lumbar column with a minimal incision of about 2 cm. In addition to the AxiaLIF family, which has been used in over 20,000 surgeries worldwide, the company also markets the Vectre™ Facet Fusion System for posterior fixation.